

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 Under  
the Securities Exchange Act of 1934**

May 22, 2002

**Forbes Medi-Tech Inc.**  
(Commission File No. 0-30076)

**200-750 West Pender Street  
Vancouver, British Columbia, Canada V6C 2T8**  
(Address of principal executive offices)

**PROCESSED**

**JUN 14 2002**

**THOMSON  
FINANCIAL**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): \_\_\_\_\_

**Exhibit Index**

Exhibit No.

Description

1.

Press Release


May 22, 2002

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Forbes Medi-Tech Inc.

Date: May 22, 2002

By: A handwritten signature in black ink, appearing to read 'Charles Butt', is written over a horizontal line. The signature is stylized and includes a large loop at the end.

Charles Butt  
President & CEO


**Forbes Medi-Tech to Hold Annual General Meeting on June 26, 2002**

**Vancouver, British Columbia – May 22, 2002** – Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) will hold its 2002 Annual General Meeting (AGM) at Vancouver's Four Seasons Hotel, 791 West Georgia Street, on Wednesday, June 26, 2002 at 2:00 p.m. (Pacific Standard Time).

The location of Forbes' AGM has now been changed from Toronto to Vancouver. This is in response to requests from the Company's largest base of shareholders in western Canada.

At the AGM, the Company will provide an update of its fiscal 2001 financial results, provide financial projections for fiscal 2002, and progress reports on the Company's phytosterol commercialization and pharmaceutical research and development programs.

**ON BEHALF OF THE BOARD OF DIRECTORS OF FORBES MEDI-TECH INC.**



**Charles Butt**  
President & CEO

###

*Forbes Medi-Tech Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceuticals and nutraceutical products derived from nature. By extracting plant sterols from wood pulping by-products, Forbes is developing cholesterol-lowering agents to be used both as pharmaceutical therapeutics and functional food ingredients in the battle against heart disease. Phytrol™ is a registered trademark of Forbes Medi-Tech Inc.*

**For more information, please contact:**

Martin Livingston  
Director, Investor Relations  
Telephone: (604) 681-8976  
E-mail: [irinfo@forbesmedi.com](mailto:irinfo@forbesmedi.com)

RJ (Don) MacDonald  
Chief Financial Officer  
Telephone: (604) 689-5899  
E-mail: [drnacdonald@forbesmedi.com](mailto:drnacdonald@forbesmedi.com)

*The NASDAQ National Market and the Toronto Stock Exchange have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This Press Release contains forward-looking statements concerning anticipated revenue to be received by the Company, and other information in future periods. Forward-looking statements are statements about the future and are inherently uncertain, and actual achievements of the Company and other results and occurrences may differ materially from those reflected in the forward-looking statements due to a variety of risks, uncertainties and other factors, including, without limitation, the Company's need for funding by the third quarter of 2002, which funding may not be available to the Company on acceptable terms or at all, uncertainty that the purchaser of the Amqui property will make the scheduled payments on time or at all, or that the purchase and sale transaction will close as anticipated or at all; risks respecting the completion and outcome of clinical trials; regulatory risks; marketing / manufacturing risks; strategic alliance risks; intellectual property risks; risks inherent in functional food and pharmaceutical research and clinical trials which may cause any particular research projects and/or clinical trials to be discontinued; the need to control costs and the possibility of unanticipated expenses; uncertainty as to the Company's ability to successfully increase production quantities of AD / ADD on a cost effective basis; risks with respect to foreign operations including changes in government policies; the need for regulatory approvals to market the Company's sterol-based food ingredient; uncertainty as to market acceptance of the Company's products and the Company's ability to generate projected sales volumes and product prices; the need for continued cooperation and performance by the Company's strategic partners; uncertainty as to the successful conclusion of sales discussions currently underway, and of those anticipated, with third party purchasers. The Company's forward-looking statements are based on the beliefs, expectations and opinions of management on the date the statements are made, and the Company does not assume any obligation to update forward-looking statements if circumstances or management's beliefs, expectations or opinions should change. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.*